Factors affecting the uptake of new medicines: a systematic literature review

Ágnes Lublóy, Ágnes Lublóy

Abstract

Background: The successful diffusion of new drugs is crucial for both pharmaceutical companies and patients-and of wider stakeholder concern, including for the funding of healthcare provision. Micro-level characteristics (the socio-demographic and professional characteristics of medical professionals), meso-level characteristics (the prescribing characteristics of doctors, the marketing efforts of pharmaceutical companies, interpersonal communication among doctors, drug attributes, and the characteristics of patients), and macro-level characteristics (government policies) all influence the diffusion of new drugs. This systematic literature review examines the micro- and meso-level characteristics of early prescribers of newly introduced drugs. Understanding the characteristics of early adopters may help to speed up the diffusion process, promote cost-efficient prescribing habits, forecast utilisation, and develop targeted intervention strategies.

Methods: The PubMed and Scopus electronic databases were chosen for their extensive coverage of the pertinent literature and used to identify 205 potentially relevant studies by means of a four-layered search string. The 35 studies deemed eligible were then synthetized carefully and critically, to extract variables relevant to this review.

Results: Early adoption of new drugs is not a personal trait, independent of drug type, but early adopters share both micro- and meso-level characteristics. At prescriber level, doctors' interest in particular therapeutic areas, participation in clinical trials, and volume of prescribing-either in total or within the therapeutic class of the new drug-increase the likelihood of early adoption. The marketing efforts of pharmaceutical companies and doctors' professional and social interactions leading to prescribing contagion are very powerful predictors of new drug uptake. At patient level, doctors with younger patients, patients with higher socioeconomic statuses and/or patients with poorer health statuses are more inclined to prescribe new drugs early. In contrast, the socio-demographic characteristics of prescribers and many practice-related factors play little role in the adoption process.

Conclusions: The most powerful predictors of new drug uptake include the doctors' strong scientific commitment, high prescribing volume in total or in within the therapeutic class of the new drug, high exposure to marketing, and intense communication with colleagues.

Figures

Figure 1
Figure 1
Flow diagram of the search strategy. *The full texts of the 51 potentially relevant studies were assessed by Ágnes Lublóy (100%) and Gábor Benedek (12%). The colleagues agreed on all studies reviewed together.

References

    1. Tamblyn R, McLeod P, Hanley JA, Girard N, Hurley J. Physician and practice characteristics associated with the early utilization of new prescription drugs. Med Car. 2003;41:895–908. doi: 10.1097/00005650-200308000-00004.
    1. Walley T, Mrazek M, Mossialos E. Regulating pharmaceutical markets: improving efficiency and controlling costs in the UK. Int J Health Plann Manage. 2005;20:375–398. doi: 10.1002/hpm.820.
    1. Food and Drug Administration (FDA) Summary of FDA Approvals & Receipts, 1938 to the present. 2014.
    1. Berwick DM. Disseminating innovations in health care. JAMA. 2003;289:1969–1975. doi: 10.1001/jama.289.15.1969.
    1. Ohlsson H, Chaix B, Merlo J. Therapeutic traditions, patient socioeconomic characteristics and physicians’ early new drug prescribing: a multilevel analysis of rosuvastatin prescription in South Sweden. Eur J Clin Pharmacol. 2009;65:141–150. doi: 10.1007/s00228-008-0569-4.
    1. Groves KEM, Schellinck T, Sketris I, MacKinnon NJ. Identifying early prescribers of cycloxygenase-2 inhibitors (COX-2 s) in Nova Scotia, Canada: considerations for targeted academic detailing. Res Social Adm Pharm. 2010;6:257–267. doi: 10.1016/j.sapharm.2009.09.003.
    1. Coleman JS, Katz E, Menzel H. Medical Innovation: A Diffusion Study. New York: Bobbs-Merrill Company; 1966.
    1. McGettigan P, Golden J, Fryer J, Chan R, Feely J. Prescribers prefer people: the sources of information used by doctors for prescribing suggest that the medium is more important than the message. Br J Clin Pharmacol. 2001;51:184–189. doi: 10.1111/j.1365-2125.2001.01332.x.
    1. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol. 1995;142:1103–1112.
    1. Prosser H, Walley T. New drug prescribing by hospital doctors: the nature and meaning of knowledge. Soc Sci Med. 2006;62:1565–1578. doi: 10.1016/j.socscimed.2005.08.035.
    1. Greving JP, Denig P, Van Der Veen WJ, Beltman FW, Sturkenboom MCJM, Haaijer-Ruskamp FM. Determinants for the adoption of angiotensin II receptor blockers by general practitioners. Soc Sci Med. 2006;63:2890–2898. doi: 10.1016/j.socscimed.2006.07.019.
    1. Iyengar R, Van den Bulte C, Valente TW. Opinion leadership and social contagion in new product diffusion. Market Sci. 2011;30:195–212. doi: 10.1287/mksc.1100.0566.
    1. Liu Q, Gupta S. A micro-level diffusion model for new drug adoption. J Prod Innovat Manag. 2012;29:372–384. doi: 10.1111/j.1540-5885.2012.00912.x.
    1. Mark TL, Dirani R, Slade E, Russo PA. Access to new medications to treat schizophrenia. J Behav Health Ser R. 2002;29:15–29. doi: 10.1007/BF02287829.
    1. Van den Bulte C, Lilien GL. Medical innovation revisited: social contagion versus marketing effort. Am J Sociol. 2001;106:1409–1435. doi: 10.1086/320819.
    1. Álvárez MJL, Hernández MJR. Variabilidad en la utilización de nuevos medicamentos en un área de atención primaria (in Spanish with English abstract) Rev Es Salud Public. 2005;79:379–389. doi: 10.1590/S1135-57272005000300006.
    1. Behan K, Cutts C, Tett SE. Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors. Eur J Clin Pharmacol. 2005;61:55–58. doi: 10.1007/s00228-004-0865-6.
    1. Bourke J, Roper S. In with the new: the determinants of prescribing innovation by general practitioners in Ireland. Eur J Health Econ. 2012;13:393–407. doi: 10.1007/s10198-011-0311-5.
    1. Corrigan MH, Glass HE. Physician participation in clinical studies and subsequent prescribing of new drugs. P&T. 2005;30:60–66.
    1. Dybdahl T, Andersen M, Søndergaard J, Kragstrup J, Kristiansen IS. Does the early adopter of drugs exist? A population-based study of general practitioners’ prescribing of new drugs. Eur J Clin Pharmacol. 2004;60:667–672. doi: 10.1007/s00228-004-0797-1.
    1. Dybdahl T, Andersen M, Kragstrup J, Kristiansen IS, Søndergaard J. General practitioners’ adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study. Br J Clin Pharmacol. 2005;60:526–533. doi: 10.1111/j.1365-2125.2005.02463.x.
    1. Dybdahl T, Søndergaard J, Kragstrup J, Kristiansen IS, Andersen M. Primary care physicians’ adoption of new drugs is not associated with their clinical interests: a pharmacoepidemiologic study. Scand J Prim Health. 2011;29:117–121. doi: 10.3109/02813432.2011.570024.
    1. Florentinus SR, Van Hulten R, Kloth ME, Heerdink ER, Griens AF, Leufkens HG, Groenewegen PP. The effect of pharmacotherapy audit meetings on early new drug prescribing by general practitioners. Ann Pharmacother. 2007;41:319–324. doi: 10.1345/aph.1H250.
    1. García LM, Cabeza BJ, Rodríguez EM, Alegre DRE, Rabadán AA. Adoption of new medications by prescribing physicians: the innovator physician. Aten Prim. 2000;25:22–28. doi: 10.1016/S0212-6567(00)78458-7.
    1. Garjón FJ, Azparren A, Vergara I, Azaola B, Loayssa JR. Adoption of new drugs by physicians: a survival analysis. BMC Health Serv Res. 2012;12:56. doi: 10.1186/1472-6963-12-56.
    1. Glass HE. Physician participation in market support clinical studies and subsequent prescribing behaviour. J Pharm Mark Manage. 2003;15:3–16. doi: 10.3109/J058v15n04_02.
    1. Glass HE. Do clinical grant payment practices in phase 3 clinical trials influence subsequent clinical investigator prescribing behavior? Dis Manag. 2004;7:77–87. doi: 10.1089/109350704322919014.
    1. Glass HE, Rosenthal B. Demographics, practices, and prescribing characteristics of physicians who are early adopters of new drugs. P&T. 2004;29:2–8.
    1. Glass HE, Rosenthal B. Post-launch clinical investigator drug prescribing in the US. Int J Pharm Med. 2005;19:97–104. doi: 10.2165/00124363-200519020-00005.
    1. Glass HE, Dalton DW. Profiles of phase IV investigators and subsequent prescribing of the study drug. J Pharm Mark Manage. 2006;17:3–17. doi: 10.3109/J058v17n03_02.
    1. Griffin JP, Griffin TD. The economic implications of therapeutic conservatism. J Roy Coll Phys Lond. 1993;27:121–125.
    1. Helin-Salmivaara A, Huupponen R, Virtanen A, Klaukka T. Adoption of celecoxib and rofecoxib: a nationwide database study. J Clin Pharm Ther. 2005;30:145–152. doi: 10.1111/j.1365-2710.2005.00627.x.
    1. Huskamp HA, O’Malley AJ, Horvitz-Lennon M, Taub AL, Berndt ER, Donohue JM. How quickly do physicians adopt new drugs? The case of second-generation antipsychotics. Psychiatr Serv. 2013;64:324–330. doi: 10.1176/appi.ps.201200186.
    1. Inman W, Pearce G. Prescriber profile and post-marketing surveillance. Lancet. 1993;342:658–661. doi: 10.1016/0140-6736(93)91763-C.
    1. Kozyrskyj A, Raymond C, Racher A. Characterizing early prescribers of newly marketed drugs in Canada: a population-based study. Eur J Clin Pharmacol. 2007;63:597–604. doi: 10.1007/s00228-007-0277-5.
    1. Lin SJ, Jan KA, Kao JT. Colleague interactions and new drug prescribing behavior: the case of the initial prescription of antidepressants in Taiwanese medical centers. Soc Sci Med. 2011;73:1208–1213. doi: 10.1016/j.socscimed.2011.06.065.
    1. Liu YM, Kao Yang YH, Hsieh CR. The determinants of the adoption of pharmaceutical innovation: evidence from Taiwan. Soc Sci Med. 2011;72:919–927. doi: 10.1016/j.socscimed.2010.12.027.
    1. Manchanda P, Xie Y, Youn N. The role of targeted communication and contagion in product adoption. Market Sci. 2008;27:961–976. doi: 10.1287/mksc.1070.0354.
    1. Mizik N, Jacobson R. Are physicians “easy marks”? Quantifying the effects of detailing and sampling on new prescriptions. Manage Sci. 2004;50:1704–1715. doi: 10.1287/mnsc.1040.0281.
    1. Steffensen FH, Sörensen H, Olesen F. Diffusion of new drugs in Danish general practice. Fam Pract. 1999;16:407–413. doi: 10.1093/fampra/16.4.407.
    1. Ruof J, Mittendorf T, Pirk O, Von Der Schulenburg JM. Diffusion of innovations: treatment of Alzheimer’s disease in Germany. Health Policy. 2002;60:59–66. doi: 10.1016/S0168-8510(01)00191-9.
    1. Jones MI, Greenfield SM, Bradley CP, Jowett S. Prescribing new drugs: a survey of hospital consultants in the West Midlands. Int J Pharm Pract. 2000;8:285–290. doi: 10.1111/j.2042-7174.2000.tb01017.x.
    1. Jacoby A, Smith M, Eccles M. A qualitative study to explore influences on general practitioners’ decisions to prescribe new drugs. Br J Gen Pract. 2003;53:120–125.
    1. Prosser H, Walley T. New drug uptake: qualitative comparison of high and low prescribing GPs’ attitudes and approach. Fam Pract. 2003;20:583–591. doi: 10.1093/fampra/cmg516.
    1. American Board of Physician Specialties (ABPS) Physician Board Certification Defined. 2013.
    1. Peay MY, Peay ER. Patterns of preference for information sources in the adoption of new drugs by specialists. Soc Sci Med. 1990;31:467–476. doi: 10.1016/0277-9536(90)90042-Q.
    1. Chauhan D, Mason A. Factors affecting the uptake of new medicines in secondary care: a literature review. J Clin Pharm Ther. 2008;33:339–348. doi: 10.1111/j.1365-2710.2008.00925.x.
    1. Manchanda P, Honka E. Effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. Yale J Health Policy Law Ethics. 2005;5:785–822.
    1. Prosser H, Almond S, Walley T. Influence on GPs’ decision to prescribe new drugs: the importance of who says what. Fam Pract. 2003;20:61–68. doi: 10.1093/fampra/20.1.61.
    1. Peay MY, Peay ER. Innovation in high risk drug therapy. Soc Sci Med. 1994;39:39–52. doi: 10.1016/0277-9536(94)90164-3.
    1. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. N Engl J Med. 2002;346:498–505. doi: 10.1056/NEJMsa012075.
    1. Groves KEM, Flanagan PS, MacKinnon NJ. Why physicians start or stop prescribing a drug: literature review and formulary implications. Formulary. 2002;37:186–194.
    1. Burt RS. Social contagion and innovation: cohesion versus structural equivalence. Am J Sociol. 1987;92:1287–1335. doi: 10.1086/228667.
    1. Kremer S, Bijmolt TH, Leeflang PS, Wieringa JE. Generalizations on the effectiveness of pharmaceutical promotional expenditures. Inf J Res Mark. 2008;25:234–246. doi: 10.1016/j.ijresmar.2008.08.001.
    1. Azoulay P. Do pharmaceutical sales respond to scientific evidence? J Econ Manage Strat. 2002;11:551–594. doi: 10.1162/105864002320757262.
    1. Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T. An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts. J Ment Health Policy. 2002;5:3–20.
    1. Cleary JD. Impact of pharmaceutical sales representatives on physician antibiotic prescribing. J Pharm Technol. 1992;8:27–29.
    1. Lilien GL, Rao AG, Kalish S. Bayesian estimation and control of detailing effort in a repeat purchase diffusion environment. Manage Sci. 1981;27:493–506. doi: 10.1287/mnsc.27.5.493.
    1. Gönül FF, Carter F, Petrova E, Srinivasan K. Promotion of prescription drugs and its impact on physicians’ choice behaviour. J Market. 2001;65:79–90. doi: 10.1509/jmkg.65.3.79.18329.
    1. Manchanda P, Chintagunta PK. Responsiveness of physician prescription behavior to salesforce effort: an individual level analysis. Market Lett. 2004;15:129–145. doi: 10.1023/B:MARK.0000047389.93584.09.
    1. Manchanda P, Rossi PE, Chintagunta PK. Response modeling with nonrandom marketing-mix variables. J Market Res. 2004;42:467–478. doi: 10.1509/jmkr.41.4.467.47005.
    1. Gilbody S, Wilson P, Watt I. Benefits and harms of direct to consumer advertising: a systematic review. Qual Saf Health Care. 2005;14:246–250. doi: 10.1136/qshc.2004.012781.
    1. Donohue JM, Berndt ER. Effects of direct-to-consumer advertising on medication choice: the case of antidepressants. J Public Policy Mark. 2004;23:115–127. doi: 10.1509/jppm.23.2.115.51395.
    1. Iizuka T, Jin GZ. Direct to consumer advertising and prescription choice. J Ind Econ. 2007;55:771. doi: 10.1111/j.1467-6451.2007.00329.x.
    1. Narayanan S, Desiraju R, Chintagunta PK. Return on investment implications for pharmaceutical promotional expenditures: the role of marketing-mix interactions. J Marketing. 2004;68:90–105. doi: 10.1509/jmkg.68.4.90.42734.
    1. Wosińska M. Harvard Business School Marketing Research Papers, Volume No. 02–04. 2002. Just what the patient ordered? Direct-to-consumer advertising and the demand for pharmaceutical products.
    1. Rosenthal MB, Berndt ER, Donohue JM, Epstein AM, Frank RG. Demand effects of recent changes in prescription drug promotion. Frontiers Health Policy Res. 2003;6:1–26.
    1. Williamson PM. The adoption of new drugs by doctors practising in group and solo practice. Soc Sci Med. 1975;9:233–236. doi: 10.1016/0037-7856(75)90027-X.
    1. Weiss R, Charney E, Baumgardner RA, German PS, Mellits ED, Skinner EA, Williamson JW. Changing patient management: what influences the practicing pediatrician? Pediatrics. 1990;85:791–795.
    1. Van den Bulte C, Lilien GL. Working Paper. Wharton School: University of Pennsylvania; 2001. Two-stage partial observability models of innovation adoption.
    1. Mason A. New medicines in primary care: a review of influences on general practitioner prescribing. J Clin Pharm Ther. 2008;33:1–10. doi: 10.1111/j.1365-2710.2008.00875.x.
    1. Tobin L, Almedia Neto AC, Wutzke S, Patterson C, Mackson J, Weekes L, Williamson M. Influences on the prescribing of new drugs. Aust Fam Physician. 2008;37:78–81.
    1. Winkleby MA, Jatulis DE, Frank E, Fortmann SP. Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. Am J Public Health. 1992;82:816–820. doi: 10.2105/AJPH.82.6.816.
    1. Bensing JM, Van Den Brink-Muinen A, De Bakker DH. Gender differences in practice style: a Dutch study of general practitioners. Med Car. 1993;31:219–229. doi: 10.1097/00005650-199303000-00004.
    1. Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau ME. International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol. 2012;19:e165. doi: 10.3747/co.19.946.
    1. Godman B, Wettermark B, Van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, Gustafsson LL. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol. 2014;5:106.
    1. Gustafsson LL, Wettermark B, Godman B, Andersén‒Karlsson E, Bergman U, Hasselström J, von Bahr C. The ‘wise list’–a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108:224–233. doi: 10.1111/j.1742-7843.2011.00682.x.
    1. Björkhem-Bergman L, Andersén-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, Gustafsson LL. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol. 2013;69:73–78. doi: 10.1007/s00228-013-1497-5.
    1. Pham HH, O’Malley AS, Bach PB, Saiontz-Martinez C, Schrag D. Primary care physicians’ links to other physicians through Medicare patients: the scope of care coordination. An Intern Med. 2009;150:236–242. doi: 10.7326/0003-4819-150-4-200902170-00004.
    1. Barnett ML, Landon BE, O’Malley AJ, Keating NL, Christakis NA. Mapping physician networks with self-reported and administrative data. Health Serv Res. 2011;46:1592–1609. doi: 10.1111/j.1475-6773.2011.01262.x.
    1. Landon BE, Keating NL, Barnett ML, Onnela JP, Paul S, O’Malley AJ, Keegan T, Christakis NA. Variation in patient-sharing networks of physicians across the United States. JAMA. 2012;308:265–273.
    1. Florentinus SR, Heerdink ER, Van Dijk L, Griens AMGF, Groenewegen PP, Leufkens HGM. Is new drug prescribing in primary care specialist induced? BMC Health Serv Res. 2009;9:6. doi: 10.1186/1472-6963-9-6.
    1. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behaviour of physicians. Am J Med. 1982;73:4–8. doi: 10.1016/0002-9343(82)90911-1.
    1. Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med. 1988;26:1183–1189. doi: 10.1016/0277-9536(88)90149-9.
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner